152.78 | +0.59 / +0.39%Today’s Change | 99.97 Today|||52-Week Range 154.55 | +17.93% Year-to-Date |
SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $5.5B |
Company Description
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through three segments include: Biotechnology, Protein Platforms, and Diagnostics Divisions. The Biotechnology segment is a suppliers of specialized proteins, such as cytokines, growth factors, immunoassays, antibodies and related reagents, to the biotechnology research community. The Protein Platforms segment develops and manufactures instrumentation and related consumables designed to simplify protein analysis processes along with single cell protein analysis, all under the ProteinSimple brand. The Diagnostics Divisions segment serves the clinical markets with regulated products such as controls, calibrators, reagents and immunoassays intended for diagnostic uses. The company was founded on July 17, 1981 and is headquartered in Minneapolis, MN.
Employees

Shareholders
Mutual fund holders | 58.28% |
Other institutional | 39.86% |
Individual stakeholders | 0.64% |
Top Executives
Charles R. Kummeth | President, Chief Executive Officer & Director |
James T. Hippel | CFO, Chief Accounting Officer & VP-Finance |
J. Fernando Bazan | Chief Technology Officer |
Brenda S. Furlow | Secretary, Senior Vice President & General Counsel |
Norman David Eansor | Senior Vice President |